RayKnowChina Research Map
Shortlist

Yangzhou

Northern Jiangsu People's Hospital

江苏省苏北人民医院

Listed for 11 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Northern Jiangsu People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌11 papers led
  2. Hepatocellular carcinoma肝细胞癌24 papers led4 open trials led
  3. Stomach cancer胃癌55 papers led1 open trial led
  4. Osteosarcoma骨肉瘤3 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  6. Neuroblastoma神经母细胞瘤0 papers led
  7. Haemophilia A血友病 A0 papers led
  8. IgG4-related diseaseIgG4相关性疾病2 papers led
  9. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  10. IgA nephropathyIgA 肾病2 papers led
  11. Osteogenesis imperfecta成骨不全症1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 11 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 3320242025: 332025

1 hospital in Yangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyImaging & AISurgery
Departments in papersMedical oncologyGastroenterology / hepatology
Papers it led11
  1. Development of a nomogram based on body composition and tumor burden indicators to predict lymph node metastasis in patients with T1 esophageal squamous cell carcinoma.2025BMC cancerFree full text
  2. Clinical Benefits of Combination Immunotherapy Over Standard Immunotherapy Monotherapy in Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.2025Cancer medicineFree full text
  3. Nomogram based on a novel nutritional immune-inflammatory status score to predict postoperative outcomes in esophageal squamous cell carcinoma.2025World journal of gastroenterologyFree full text
  4. Vasculogenic mimicry triggers early recidivation and resistance to adjuvant therapy in esophageal cancer.2024BMC cancerFree full text
  5. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.2024Drug design, development and therapyFree full text
  6. Combining fecal microbiome and metabolomics reveals diagnostic biomarkers for esophageal squamous cell carcinoma.2024Microbiology spectrumFree full text
  7. PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling.2023BMC cancerFree full text
  8. Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma.2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  9. USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.2023Medical oncology (Northwood, London, England)
  10. TM4SF1 promotes esophageal squamous cell carcinoma metastasis by interacting with integrin α6.2022Cell death & diseaseFree full text
  11. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.2021International journal of radiation oncology, biology, physics
Chinese-language papers (not in the count)1
  1. [Progress in autoantibodies associated with esophageal squamous cell carcinoma].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status8
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  3. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  6. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  7. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  8. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)12
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Figsharesupplementary-materials
  3. Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio2025Figsharearticle
  4. Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Preoperative Immunotherapy Combined with Chemotherapy: Evaluation of Nutritional and Immune-inflammatory Status in ESCC and Its Impact on Perioperative Period2024Research Squarepreprint
  6. WITHDRAWN: Clinical characterization and immunosuppressive regulation of DNAJCB5B in Esophageal Squamous Cell Carcinoma2024Research Squarepreprint
  7. WITHDRAWN: Clinical characterization and immunosuppressive regulation of DNAJCB5B in Esophageal Squamous Cell Carcinoma2024Research Squarepreprint
  8. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  9. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  10. P-100 CXCL8 is a valid potential prognostical marker for esophageal squamous cell carcinoma2022Annals of Oncologyconference-abstract
  11. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  12. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 24 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
24
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 8820242025: 992025

1 hospital in Yangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07811687

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  2. Recruiting
    Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07337421

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  3. Recruiting
    Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07337460

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  4. Recruiting
    CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05433467

    Age 18 years to Not stated (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)Recurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led24
  1. Integrative Analysis the Role of ENG as a Metabolic and Macrophage-Related Gene in Hepatocellular Carcinoma.2026Biochemical genetics
  2. Hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) showing iso- or hyperintensity in the hepatobiliary phase: differentiation using Gd-EOB-DTPA enhanced MRI radiomics and deep learning features.2025BMC medical imagingFree full text
  3. MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis.2025Cell death & diseaseFree full text
  4. CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling.2025Cell death & diseaseFree full text
  5. Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?2025Hepatology international
  6. Cross-talks of GSH, mitochondria, RNA m6A modification, NRF2, and p53 between ferroptosis and cuproptosis in HCC: A review.2025International journal of biological macromolecules
  7. Amide proton transfer-weighted MRI distinguishes hepatocellular carcinoma from mass-forming intrahepatic cholangiocarcinoma.2025Magnetic resonance imaging
  8. FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling.2025Medical oncology (Northwood, London, England)
  9. Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential.2025Medical oncology (Northwood, London, England)
  10. Enhanced prediction of 5-year postoperative recurrence in hepatocellular carcinoma by incorporating LASSO regression and random forest models.2025Surgical endoscopy
  11. How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?2024Abdominal radiology (New York)
  12. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.2024Cardiovascular and interventional radiology
  13. Transarterial chemoembolization combined with microwave ablation versus repeated resection for recurrent small hepatocellular carcinoma after resection: What is the better treatment?2024Clinical radiology
  14. TRIM5 as a promising diagnostic biomarker of hepatocellular carcinoma: integrated analysis and experimental validation.2024Functional & integrative genomics
  15. Identification of Antisense RNA NRAS-AS and Its Preliminary Exploration of the Anticancer Regulatory Mechanism.2024GenesFree full text
  16. Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma.2024Journal for immunotherapy of cancerFree full text
  17. Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  18. Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  19. RNF173 suppresses RAF/MEK/ERK signaling to regulate invasion and metastasis via GRB2 ubiquitination in Hepatocellular Carcinoma.2023Cell communication and signaling : CCSFree full text
  20. Wogonin Induces Cell Cycle Arrest and Apoptosis of Hepatocellular Carcinoma Cells by Activating Hippo Signaling.2022Anti-cancer agents in medicinal chemistry
  21. CD36 accelerates the progression of hepatocellular carcinoma by promoting FAs absorption.2022Medical oncology (Northwood, London, England)
  22. Emerin knockdown induces the migration and invasion of hepatocellular carcinoma cells by up-regulating the cytoplasmic p21.2022Neoplasma
  23. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.2021Experimental cell research
  24. Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml.2021Frontiers in public healthFree full text
Chinese-language papers (not in the count)1
  1. [Study on the correlation between high expression of GIT1 and M2 macrophage infiltration and prognosis in hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune FunctionRecruitingNCT07811687Lead sponsorStart 2026-08
  2. Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence FactorsRecruitingNCT07337421Lead sponsorPhase 2Start 2025-09
  3. Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence FactorsRecruitingNCT07337460Lead sponsorPhase 2Start 2025-11
  4. CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical ResectionRecruitingNCT05433467Lead sponsorN/AStart 2022-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 55 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
55
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 101020232024: 222220242025: 17172025

1 hospital in Yangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06741501

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIEarly detection & endoscopy
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led55
  1. IKZF3 promotes gastric cancer progression via Hedgehog signaling activation and is targetable by SANT-1.2025Acta biochimica et biophysica SinicaFree full text
  2. ASO Author Reflections: Unlocking the Potential of Noncoding RNAs in Gastric Cancer: From Molecular Insights to Precision Treatment.2025Annals of surgical oncology
  3. ncRNAs as Key Regulators in Gastric Cancer: From Molecular Subtyping to Therapeutic Targets.2025Annals of surgical oncology
  4. PWP1 transcriptionally regulates p53, modulating apoptosis and cell cycle to promote gastric cancer progression.2025Apoptosis : an international journal on programmed cell deathFree full text
  5. A comparison of postoperative outcomes between robotic-assisted and laparoscopic-assisted total gastrectomy: a comprehensive meta-analysis and systematic review.2025BMC surgeryFree full text
  6. Exosomes play a crucial role in remodeling the tumor microenvironment and in the treatment of gastric cancer.2025Cell communication and signaling : CCSFree full text
  7. Targeted therapy for KIF3C: A study on the mechanism of combined therapy with KIF3C signaling pathway, afatinib, and MT-DC (ac)phosphoramide in regulating gastric cancer cell proliferation.2025Cellular signalling
  8. A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  9. PAMAM/miR-144 nanocarrier system inhibits the migration of gastric cancer by targeting mTOR signal transduction pathway.2025Colloids and surfaces. B, Biointerfaces
  10. A 3-Arm case-matched analysis of anti-reflux reconstruction methods after laparoscopic proximal gastrectomy - Single tract jejunal interposition vs double tract reconstruction vs tube-like stomach reconstruction.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyRCT
  11. Long-term muscle-sparing benefits of proximal gastrectomy in elderly patients with upper-third early gastric cancer: A propensity score-matched analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. Evaluation of combined tubular gastroesophageal anastomosis and C-shaped flap technique in proximal gastrectomy for gastric cancer: A retrospective propensity score matching analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Development and external validation of nomogram associated with gastroparesis syndrome after subtotal gastrectomy depending on random forest and traditional model: does robotic surgery have advantages?2025Journal of robotic surgery
  14. The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates.2025Molecular cancerFree full text
  15. Development and validation of a prognostic model for cachexia in postoperative gastric cancer patients with low nutritional risk: a dual-center retrospective cohort study.2025Surgical endoscopy
  16. Comparison of channel esophagogastrostomy and double tract reconstruction after laparoscopic-assisted proximal gastrectomy: a propensity score-matched analysis.2025Surgical endoscopy
  17. Nomogram for pre-procedural prediction of lymph node metastasis in patients with submucosal early gastric cancer.2025Surgical endoscopy
  18. PACSIN1 promotes immunosuppression in gastric cancer by degrading MHC-I.2024Acta biochimica et biophysica SinicaFree full text
  19. FANCA facilitates G1/S cell cycle advancement, proliferation, migration and invasion in gastric cancer.2024Acta biochimica et biophysica SinicaFree full text
  20. Sentinel Node Navigation Surgery for Early Gastric Cancer: A Narrative Review.2024American journal of clinical oncology
  21. R-type gastrojejunostomy after total laparoscopic radical gastrectomy for distal gastric cancer.2024Asian journal of surgery
  22. GGT5 facilitates migration and invasion through the induction of epithelial-mesenchymal transformation in gastric cancer.2024BMC medical genomicsFree full text
  23. Modified Q-type purse-string suture duodenal stump embedding method for laparoscopic gastrectomy for gastric cancer.2024BMC surgeryFree full text
  24. The impact of laparoscopic radical gastrectomy on the inflammatory response and immune function of patients with gastric cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  25. ACTL8 Promotes the Progression of Gastric Cancer Through PI3K/AKT/mTOR Signaling Pathway.2024Digestive diseases and sciencesFree full text
  26. Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies.2024European journal of clinical investigation
  27. BHLHE40-mediated transcriptional activation of GRIN2D in gastric cancer is involved in metabolic reprogramming.2024Functional & integrative genomics
  28. Helicobacter pylori Therapy and Risk of Gastric Cancer After Endoscopic Resection of Dysplasia: A Sensitivity Analysis Assessing Impact of Unmeasured Confounding.2024Gastroenterology
  29. Transcription Factor E2F4 Promote Proliferation, Migration, and Invasion of Gastric Cancer Cells by transcriptionally activating DSCC1.2024International journal of biological sciencesFree full text
  30. Role and research progress of spasmolytic polypeptide‑expressing metaplasia in gastric cancer (Review).2024International journal of oncologyFree full text
  31. The benefits of R anastomotic technique for Billroth-II reconstruction with Braun anastomosis during totally laparoscopic distal gastrectomy: a propensity score matching analysis.2024International journal of surgery (London, England)Free full text
  32. Analysis of Clinical Efficacy and Quality of Life of Braun Anastomosis in Gastrointestinal Reconstruction in Totally Laparoscopic Distal Gastrectomy: A Single-Center Retrospective Study.2024Journal of gastrointestinal cancer
  33. Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.2024Journal of gastrointestinal cancer
  34. Celastrus orbiculatus extract suppresses gastric cancer stem cells through the TGF-β/Smad signaling pathway.2024Journal of natural medicines
  35. Upper abdominal pain in a young female treated by endoscopic submucosal dissection.2024Revista espanola de enfermedades digestivas
  36. An unusual cause of life-threatening upper gastrointestinal bleeding.2024Revista espanola de enfermedades digestivas
  37. Surgical options and survival prognosis in geriatric patients beyond average lifespan with locally advanced gastric cancer: a propensity score-matched analysis.2024Surgical endoscopy
  38. A retrospective study of provisional outcomes of intracorporeal esophagojejunostomy versus extracorporeal anastomosis during laparoscopic total gastrectomy for gastric cancer. a single -center.2024World journal of surgical oncologyFree full text
  39. Laparoscopic versus open distal gastrectomy for advanced gastric cancer in elderly patients: a propensity-score matched analysis.2024World journal of surgical oncologyFree full text
  40. Single-port versus conventional laparoscopic distal gastrectomy for gastric cancer: A systematic review and meta analysis.2023Asian journal of surgery
  41. Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer.2023BMC bioinformaticsFree full text
  42. Surgical outcomes of laparoscopic proximal gastrectomy for upper-third gastric cancer: esophagogastrostomy, gastric tube reconstruction, and double-tract reconstruction.2023BMC surgeryFree full text
  43. Risk factors for postoperative pancreatic fistula (POPF) in gastric cancer patients: A systematic review and meta-analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  44. Endoscopic submucosal dissection of a rare cardiac mass in an older woman: dendritic fibromyxolipoma.2023Gastrointestinal endoscopy
  45. Machine learning and single-cell sequencing reveal the potential regulatory factors of mitochondrial autophagy in the progression of gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  46. An unusual gastric mass mimicking a gastrointestinal stromal tumor.2023Revista espanola de enfermedades digestivas
  47. Endoscopic submucosal dissection of a rare antral mass: gastric fibrolipoma.2023Revista espanola de enfermedades digestivas
  48. Endoscopic full-thickness resection of a complete extraluminal growth gastric gastrointestinal stromal tumor with a single-channel gastroscope.2023Revista espanola de enfermedades digestivas
  49. A nomogram for predicting the recurrence of small bowel obstruction after gastrectomy in patients with gastric cancer.2023World journal of surgical oncologyFree full text
  50. The UPR signaling molecule ATF6 is a poor prognostic marker in gastric cancer.2022Asian journal of surgery
  51. Neutrophil-lymphocyte ratio combined with plasma fibrinogen is an useful predictor for the diagnosis of liver metastases from gastric cancer.2022Asian journal of surgery
  52. Galectin‑1 binds GRP78 to promote the proliferation and metastasis of gastric cancer.2022International journal of oncologyFree full text
  53. A pump-free and high-throughput microfluidic chip for highly sensitive SERS assay of gastric cancer-related circulating tumor DNA via a cascade signal amplification strategy.2022Journal of nanobiotechnologyFree full text
  54. A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).2021International journal of surgery (London, England)
  55. Establishment and verification of a nomogram for predicting the risk of lymph node metastasis in early gastric cancer.2021Revista espanola de enfermedades digestivas
All its trials on ClinicalTrials.gov, any status14
  1. Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal GastrectomyStatus unknownNCT06475170Lead sponsorN/AStart 2024-08
  2. Prediction Model of Occult Omental Metastasis in Patients With Gastric CancerStatus unknownNCT06405009Lead sponsorStart 2024-04
  3. Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy in Totally Laparoscopic Total GastrectomyStatus unknownNCT06383793Lead sponsorStart 2024-04
  4. PWP1's Expression in Gastric Cancer.CompletedNCT06392750Lead sponsorStart 2021-05
  5. Comparison of Channel Esophagogastrostomy and Double Tract Reconstruction After Laparoscopic-assist Proximal Gastrectomy: A Propensity Score-Matched AnalysisCompletedNCT06741124Lead sponsorStart 2020-09
  6. Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal GastrectomyNot yet recruitingNCT06741501Lead (inferred)N/AStart 2025-01
  7. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  8. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  9. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  10. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  11. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  12. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  13. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  14. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

2 hospitals in Yangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 112025

1 hospital in Yangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Yangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Yangzhou for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  2. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Yangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vessels
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

2 hospitals in Yangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Yangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Yangzhou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

江苏省苏北人民医院

Northern Jiangsu People's Hospital

扬州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Northern Jiangsu People's Hospital Affiliated to Yangzhou University; Subei People's Hospital of Jiangsu Province; Subei People's Hospital; Northern Jiangsu People's Hospital Affliated to Yangzhou University; Northern Jiangsu People's Hospital (Clinical Medical College; Northern Jiangsu people's Hospital; Medical Research Center of Northern Jiangsu People's Hospital; Affiliated Hospital to Yangzhou University

Suggest a correctionDownload the data